Xiaolin Shi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaolin Shi has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
Yifeng Yuan
The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310052, China
9 shared publicationsHang Zhou
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China
7 shared publicationsKang Liu
Department of Orthopedics, The Second Affiliated Hospital of Zhejiang Chinese Medical University (Xinhua Hospital of Zhejiang Province), Hangzhou, People’s Republic of China
6 shared publications- Kang Liu
The Second Affiliated Hospital of Zhejiang Chinese Medical University
6 shared publications Zechen Zhang
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310052, China
6 shared publicationsWei Xiong
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310052, China
5 shared publications
Latest Publications
- 13 July 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 375, 153527
Multifunctional 3D-printed Mg-doped bioactive glass/PLLA scaffolds with quercetin delivery for remodeling the osteoporotic microenvironment via osteogenic–angiogenic coupling and osteoclast inhibition
- 13 July 2026
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 375, 153527
Multifunctional 3D-printed Mg-doped bioactive glass/PLLA scaffolds with quercetin delivery for remodeling the osteoporotic microenvironment via osteogenic–angiogenic coupling and osteoclast inhibition
- 10 April 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (2) , 134
QiangGuYin-containing serum improves osteogenic differentiation via regulating osteoclast-derived exosomal miR-27b-3p
Osteoclast-derived exosomes play a critical role in suppressing osteogenic differentiation, contributing to postmenopausal osteoporosis (PMOP). QiangGuYin (QGY), a traditional Chinese herbal formula, has demonstrated efficacy in alleviating PMOP progression. This study aimed to elucidate the mechanism by which QGY modulates osteoclast-derived exosome-mediated inhibition of osteogenesis. Exosomes were isolated from osteoclasts treated with QGY-containing serum or control serum. Bone marrow mesenchymal stem cells (BMMSCs) were used to evaluate osteogenic differentiation by Western blotting, alkaline phosphatase (ALP) activity assay, and Alizarin Red S staining. And qRT-PCR, Western blotting, immunofluorescence and immunohistochemistry were conducted to detect the expression of miR-27b-3p, DKK2 and the activation level of β-catenin pathway. Spearman’s correlation analysis was used to evaluate relationships among exosomal miR-27b-3p, DKK2, β-catenin, and bone microarchitecture parameters. Osteoclast-derived exosomes significantly inhibited osteogenic differentiation, an effect reversed by QGY-containing serum. QGY-containing serum increased the abundance of miR-27b-3p in osteoclast-derived exosomes. MiR-27b-3p inhibitor abolished the protective effects of QGY. DKK2 was identified as a direct target of miR-27b-3p and was upregulated by osteoclast-derived exosomes but suppressed by QGY-containing serum. DKK2 overexpression blocked QGY-containing serum-mediated rescue of osteogenic differentiation and β-catenin pathway. In PMOP rats, QGY increased serum exosomal miR-27b-3p levels, suppressed DKK2 expression and enhanced β-catenin level in femoral tissues. Significant correlations were observed among exosomal miR-27b-3p, DKK2, β-catenin and bone quality indices. QGY-containing serum alleviates osteoclast-derived exosome-induced osteogenic differentiation inhibition via the miR-27b-3p/DKK2/β-catenin signaling, providing a mechanistic basis for the clinical application of QGY in PMOP treatment. Graphical abstract
- 10 April 2026
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 57 (2) , 134
QiangGuYin-containing serum improves osteogenic differentiation via regulating osteoclast-derived exosomal miR-27b-3p
Osteoclast-derived exosomes play a critical role in suppressing osteogenic differentiation, contributing to postmenopausal osteoporosis (PMOP). QiangGuYin (QGY), a traditional Chinese herbal formula, has demonstrated efficacy in alleviating PMOP progression. This study aimed to elucidate the mechanism by which QGY modulates osteoclast-derived exosome-mediated inhibition of osteogenesis. Exosomes were isolated from osteoclasts treated with QGY-containing serum or control serum. Bone marrow mesenchymal stem cells (BMMSCs) were used to evaluate osteogenic differentiation by Western blotting, alkaline phosphatase (ALP) activity assay, and Alizarin Red S staining. And qRT-PCR, Western blotting, immunofluorescence and immunohistochemistry were conducted to detect the expression of miR-27b-3p, DKK2 and the activation level of β-catenin pathway. Spearman’s correlation analysis was used to evaluate relationships among exosomal miR-27b-3p, DKK2, β-catenin, and bone microarchitecture parameters. Osteoclast-derived exosomes significantly inhibited osteogenic differentiation, an effect reversed by QGY-containing serum. QGY-containing serum increased the abundance of miR-27b-3p in osteoclast-derived exosomes. MiR-27b-3p inhibitor abolished the protective effects of QGY. DKK2 was identified as a direct target of miR-27b-3p and was upregulated by osteoclast-derived exosomes but suppressed by QGY-containing serum. DKK2 overexpression blocked QGY-containing serum-mediated rescue of osteogenic differentiation and β-catenin pathway. In PMOP rats, QGY increased serum exosomal miR-27b-3p levels, suppressed DKK2 expression and enhanced β-catenin level in femoral tissues. Significant correlations were observed among exosomal miR-27b-3p, DKK2, β-catenin and bone quality indices. QGY-containing serum alleviates osteoclast-derived exosome-induced osteogenic differentiation inhibition via the miR-27b-3p/DKK2/β-catenin signaling, providing a mechanistic basis for the clinical application of QGY in PMOP treatment. Graphical abstract
- 27 November 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 335 (Pt 2) , 149308
Engineering a therapeutic deferoxamine-mesoporous silica-naringin/poly(L-lactic acid) scaffold to reverse ferroptosis-mediated imbalance and promote osteogenic differentiation in osteoporotic microenvironment
- 27 November 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 335 (Pt 2) , 149308
Engineering a therapeutic deferoxamine-mesoporous silica-naringin/poly(L-lactic acid) scaffold to reverse ferroptosis-mediated imbalance and promote osteogenic differentiation in osteoporotic microenvironment
- Open Access
- 5 November 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1703116
The effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis
Background: Osteoporosis is a metabolic bone disease characterized by decreased bone mass and increased fracture risk. Bone turnover markers, such as osteocalcin (OC), undercarboxylated osteocalcin (ucOC), and other biochemical indicators, are important for assessing bone metabolism. Vitamin K2 influences bone metabolism by enhancing osteocalcin γ-carboxylation. Methods: This study followed PRISMA guidelines and included randomized controlled trials on the effects of vitamin K2 supplementation on bone turnover biomarkers in postmenopausal osteoporosis patients. Key outcomes included changes in OC, ucOC, and other bone metabolism markers. Results: Nine studies with 2,570 participants were included. Vitamin K2 (VK2) increased osteocalcin (OC; MD 1.86, 95% CI 1.17–2.56) and bone-specific alkaline phosphatase (BAP; MD 1.49, 95% CI 0.98–2.00). It reduced undercarboxylated OC (ucOC; WMD −1.54, 95% CI −2.44 to −0.64) and tartrate-resistant acid phosphatase (TRAP; MD −0.83, 95% CI −1.21 to −0.46). C-terminal telopeptide (CTX) showed a small, statistically significant reduction (MD −0.09, 95% CI −0.14 to −0.05) with uncertain clinical relevance. N-telopeptide (NTX) showed no significant change. Conclusions: Vitamin K2 supplementation improves key bone turnover biomarkers, particularly OC and ucOC. These findings support its role in bone metabolism, though further long-term studies are needed to confirm clinical benefits, such as increased bone mineral density. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251087067 , identifier CRD420251087067.
- 5 November 2025
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1703116
Open AccessThe effect of vitamin K2 supplementation on bone turnover biochemical markers in postmenopausal osteoporosis patients: a systematic review and meta-analysis
Background: Osteoporosis is a metabolic bone disease characterized by decreased bone mass and increased fracture risk. Bone turnover markers, such as osteocalcin (OC), undercarboxylated osteocalcin (ucOC), and other biochemical indicators, are important for assessing bone metabolism. Vitamin K2 influences bone metabolism by enhancing osteocalcin γ-carboxylation. Methods: This study followed PRISMA guidelines and included randomized controlled trials on the effects of vitamin K2 supplementation on bone turnover biomarkers in postmenopausal osteoporosis patients. Key outcomes included changes in OC, ucOC, and other bone metabolism markers. Results: Nine studies with 2,570 participants were included. Vitamin K2 (VK2) increased osteocalcin (OC; MD 1.86, 95% CI 1.17–2.56) and bone-specific alkaline phosphatase (BAP; MD 1.49, 95% CI 0.98–2.00). It reduced undercarboxylated OC (ucOC; WMD −1.54, 95% CI −2.44 to −0.64) and tartrate-resistant acid phosphatase (TRAP; MD −0.83, 95% CI −1.21 to −0.46). C-terminal telopeptide (CTX) showed a small, statistically significant reduction (MD −0.09, 95% CI −0.14 to −0.05) with uncertain clinical relevance. N-telopeptide (NTX) showed no significant change. Conclusions: Vitamin K2 supplementation improves key bone turnover biomarkers, particularly OC and ucOC. These findings support its role in bone metabolism, though further long-term studies are needed to confirm clinical benefits, such as increased bone mineral density. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251087067 , identifier CRD420251087067.
- Open Access
- 23 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
In vitro assessment of the osteogenic and antibacterial capabilities of Mg-MOF particles with encapsulated Levofloxacin within polydopamine
Infectious bone defect is a condition where infection and bone defect occur simultaneously. The simultaneous achievement of effective antimicrobial management and enhanced bone regeneration continues to present a major hurdle in musculoskeletal therapeutics. To address these limitations, we have developed a novel osteoconductive material, this material (PDA@Mg-MOF-LEV) consists of Magnesium-based metal-organic frameworks (Mg-MOF) particles loaded with the antibiotic levofloxacin (LEV) and coated with polydopamine (PDA), which integrates photothermal therapy with antibiotic delivery to combat bacterial drug resistance and facilitate bone tissue regeneration. Under near-infrared (NIR) irradiation, PDA@Mg-MOF-LEV particles demonstrate superior antibacterial efficacy and enhanced osteogenic potential. Drug release studies indicate that NIR irradiation significantly increases LEV release by 337% and Mg ions release by 196% compared to standard conditions. Furthermore, in vitro antibacterial assays confirm that NIR irradiation markedly enhances the antibacterial activity of PDA@Mg-MOF-LEV particles, achieving inhibition rates of 97.5 ± 1.45% against Escherichia coli (E. coli) and 98.5 ± 2.27% against Staphylococcus aureus (S. aureus). The photothermal therapy mediated by NIR irradiation not only enhances antibacterial efficacy but also directly stimulates osteogenic differentiation and calcium deposition in mBMSCs, positioning PDA@Mg-MOF-LEV as a multi-modal therapeutic platform for infective osteogenesis.
- 23 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessIn vitro assessment of the osteogenic and antibacterial capabilities of Mg-MOF particles with encapsulated Levofloxacin within polydopamine
Infectious bone defect is a condition where infection and bone defect occur simultaneously. The simultaneous achievement of effective antimicrobial management and enhanced bone regeneration continues to present a major hurdle in musculoskeletal therapeutics. To address these limitations, we have developed a novel osteoconductive material, this material (PDA@Mg-MOF-LEV) consists of Magnesium-based metal-organic frameworks (Mg-MOF) particles loaded with the antibiotic levofloxacin (LEV) and coated with polydopamine (PDA), which integrates photothermal therapy with antibiotic delivery to combat bacterial drug resistance and facilitate bone tissue regeneration. Under near-infrared (NIR) irradiation, PDA@Mg-MOF-LEV particles demonstrate superior antibacterial efficacy and enhanced osteogenic potential. Drug release studies indicate that NIR irradiation significantly increases LEV release by 337% and Mg ions release by 196% compared to standard conditions. Furthermore, in vitro antibacterial assays confirm that NIR irradiation markedly enhances the antibacterial activity of PDA@Mg-MOF-LEV particles, achieving inhibition rates of 97.5 ± 1.45% against Escherichia coli (E. coli) and 98.5 ± 2.27% against Staphylococcus aureus (S. aureus). The photothermal therapy mediated by NIR irradiation not only enhances antibacterial efficacy but also directly stimulates osteogenic differentiation and calcium deposition in mBMSCs, positioning PDA@Mg-MOF-LEV as a multi-modal therapeutic platform for infective osteogenesis.
- Open Access
- 4 July 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (7)
Efficacy and safety of vertebroplasty versus posterior pedicle screw in treating stage III Kummell’s disease without neurological deficits: A systematic review and meta-analysis
Objective: This study aimed to evaluate the efficacy and safety of vertebroplasty versus posterior pedicle screw fixation combined with vertebroplasty in treating stage III Kummell’s disease without neurological deficits. Method: A systematic literature search was conducted across six databases. A meta-analysis of prospective and retrospective studies meeting the inclusion criteria was conducted using Review Manager 5.4.1. Results: Eight studies (one prospective, one randomized control trial, and six retrospective) involving 409 patients were included. Vertebroplasty demonstrated advantages over posterior pedicle screw + vertebroplasty in operative time (weighted mean difference: −83.22 min; 95% confidence interval: −97.70 to −68.73; p < 0.05), blood loss (weighted mean difference: −158.65 mL; 95% confidence interval: −219.99 to −97.31; p < 0.05), and hospital stay (weighted mean difference: −5.64 days; 95% confidence interval: −7.36 to −3.92; p < 0.05). No significant differences were observed in Cobb’s angle (weighted mean difference: 1.28°; 95% confidence interval: −0.21 to 2.78; p > 0.05), relative anterior vertebral height (weighted mean difference: 2.98%; 95% confidence interval: −4.15 to 10.11; p > 0.05), cement leakage (13.2% vs. 8.5%; odds ratios: 1.67; 95% confidence interval: 0.86–3.24; p > 0.05), or wound infection (0% vs. 4.88%; odds ratios: 0.28; 95% confidence interval: 0.07–1.15; p > 0.05). Conclusion: Both vertebroplasty and posterior pedicle screw + vertebroplasty are effective for treating stage III Kummell’s disease without neurological deficits. Vertebroplasty offers superior perioperative outcomes with reduced surgical trauma and hospital stay. PROSPERO registration number: CRD420251031065.
- 4 July 2025
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 53 (7)
Open AccessEfficacy and safety of vertebroplasty versus posterior pedicle screw in treating stage III Kummell’s disease without neurological deficits: A systematic review and meta-analysis
Objective: This study aimed to evaluate the efficacy and safety of vertebroplasty versus posterior pedicle screw fixation combined with vertebroplasty in treating stage III Kummell’s disease without neurological deficits. Method: A systematic literature search was conducted across six databases. A meta-analysis of prospective and retrospective studies meeting the inclusion criteria was conducted using Review Manager 5.4.1. Results: Eight studies (one prospective, one randomized control trial, and six retrospective) involving 409 patients were included. Vertebroplasty demonstrated advantages over posterior pedicle screw + vertebroplasty in operative time (weighted mean difference: −83.22 min; 95% confidence interval: −97.70 to −68.73; p < 0.05), blood loss (weighted mean difference: −158.65 mL; 95% confidence interval: −219.99 to −97.31; p < 0.05), and hospital stay (weighted mean difference: −5.64 days; 95% confidence interval: −7.36 to −3.92; p < 0.05). No significant differences were observed in Cobb’s angle (weighted mean difference: 1.28°; 95% confidence interval: −0.21 to 2.78; p > 0.05), relative anterior vertebral height (weighted mean difference: 2.98%; 95% confidence interval: −4.15 to 10.11; p > 0.05), cement leakage (13.2% vs. 8.5%; odds ratios: 1.67; 95% confidence interval: 0.86–3.24; p > 0.05), or wound infection (0% vs. 4.88%; odds ratios: 0.28; 95% confidence interval: 0.07–1.15; p > 0.05). Conclusion: Both vertebroplasty and posterior pedicle screw + vertebroplasty are effective for treating stage III Kummell’s disease without neurological deficits. Vertebroplasty offers superior perioperative outcomes with reduced surgical trauma and hospital stay. PROSPERO registration number: CRD420251031065.
- Open Access
- 13 May 2025
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 26 (1) , 1-20
The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis
To evaluate the effectiveness of Jintiange capsules (JTG) in relieving pain in patients with primary osteoporosis (POP). A systematic review of the literature was conducted through seven databases, including PubMed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure, Wanfang Database and SinoMed, from inception to October 2023. The control group was given conventional anti-osteoporosis drug therapy such as Alfacalcidol soft capsules, Alendronate sodium tablets, Caltrate D3, etc. The experimental group was treated with JTG alone or in combination with JTG on the basis of the drugs used in the control group. The primary outcome measure was the visual analog scale (VAS). Stata SE-64 software was used to conduct meta-analyses of the final included studies. A total of 2916 participants were included in 21 articles. The results of meta-analysis showed that JTG relieved pain (WMD: -2.51; 95% CI: -3.30, -1.71; p < 0.05), improved the bone mineral density (BMD) of femoral neck (WMD: 0.83; 95% CI: 0.33, 1.33; p < 0.05) and lumbar (WMD: 1.14; 95% CI: 0.67, 1.62; p < 0.05), improved oswestry disability index (ODI) (WMD: -1.79; 95% CI: -3.05, -0.54; p < 0.05), enhanced timed up and go test (TUG) (WMD: -2.61; 95% CI: -4.60, -0.62; p < 0.05) and decreased fracture incidence (WMD: 0.37; 95% CI: 0.15, 0.93; p < 0.05). In terms of relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture, JTG is a good choice for patients with osteoporosis (OP).
- 13 May 2025
- Published by Springer Nature in BMC Musculoskeletal Disorders
- Vol. 26 (1) , 1-20
Open AccessThe effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis
To evaluate the effectiveness of Jintiange capsules (JTG) in relieving pain in patients with primary osteoporosis (POP). A systematic review of the literature was conducted through seven databases, including PubMed, Web of Science, Cochrane Library, Embase, Chinese National Knowledge Infrastructure, Wanfang Database and SinoMed, from inception to October 2023. The control group was given conventional anti-osteoporosis drug therapy such as Alfacalcidol soft capsules, Alendronate sodium tablets, Caltrate D3, etc. The experimental group was treated with JTG alone or in combination with JTG on the basis of the drugs used in the control group. The primary outcome measure was the visual analog scale (VAS). Stata SE-64 software was used to conduct meta-analyses of the final included studies. A total of 2916 participants were included in 21 articles. The results of meta-analysis showed that JTG relieved pain (WMD: -2.51; 95% CI: -3.30, -1.71; p < 0.05), improved the bone mineral density (BMD) of femoral neck (WMD: 0.83; 95% CI: 0.33, 1.33; p < 0.05) and lumbar (WMD: 1.14; 95% CI: 0.67, 1.62; p < 0.05), improved oswestry disability index (ODI) (WMD: -1.79; 95% CI: -3.05, -0.54; p < 0.05), enhanced timed up and go test (TUG) (WMD: -2.61; 95% CI: -4.60, -0.62; p < 0.05) and decreased fracture incidence (WMD: 0.37; 95% CI: 0.15, 0.93; p < 0.05). In terms of relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture, JTG is a good choice for patients with osteoporosis (OP).
- 22 January 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (3) , 2180-2191
Enhanced Three-Component Chloro-/Azido-Fluoroalkylation of Unactivated Alkenes via the Proximity Effect in a Heterogenous Metallaphotocatalyst
- 22 January 2025
- Published by American Chemical Society (ACS) in ACS Catalysis
- Vol. 15 (3) , 2180-2191
Enhanced Three-Component Chloro-/Azido-Fluoroalkylation of Unactivated Alkenes via the Proximity Effect in a Heterogenous Metallaphotocatalyst